Dix laboratoires internationaux s'associent pour tenter de modéliser le fonctionnement du cerveau humain grâce à l'intelligence artificielle. Financé à hauteur de 15 millions de dollars par Meta, ce vaste projet prévoit de collecter 15 000 heures d'activité cérébrale, avec l'espoir de faire progresser le diagnostic et le traitement des maladies neurologiques.

# Professional Summary This open-access review article, published in the Journal of the Egyptian National Cancer Institute in September 2026, examines the advancement of next-generation CAR-T cell therapies in oncology treatment. The article explores three primary dimensions: precision engineering techniques that enhance CAR-T cell design and functionality, programmable immunity mechanisms that enable dynamic therapeutic control, and emerging clinical applications expanding beyond traditional hematologic malignancies. Next-generation CAR-T therapies represent a significant evolution from first-generation approaches, incorporating sophisticated modifications to improve efficacy, reduce toxicity, and overcome current limitations such as tumor microenvironment resistance and antigen escape. The review synthesizes recent clinical findings and emerging evidence, demonstrating how engineered safeguards and adaptive immune programming are enabling broader patient populations to benefit from cellular immunotherapy. This comprehensive analysis matters substantially for oncologists, immunologists, and healthcare strategists seeking to understand the trajectory of precision cancer immunotherapy and identify opportunities for improved patient outcomes in diverse cancer types.

Researchers Mallik and Mollick have developed an innovative AI-driven framework that combines multi-modal single-cell genomics with reverse vaccinology to design personalized multi-epitope cancer vaccines. This approach leverages generative AI to establish genotype-phenotype modeling, enabling the de novo creation of cancer vaccines tailored to individual patients' molecular profiles. By integrating single-cell genomic data across multiple modalities, the framework identifies tumor-specific antigens and designs epitopes that can trigger robust immune responses against cancer cells. The methodology represents a significant advancement in personalized cancer immunotherapy, moving beyond conventional vaccine approaches by utilizing cutting-edge AI and comprehensive genomic analysis. This work, published in Frontiers in Genetics, demonstrates how artificial intelligence can accelerate the discovery and optimization of therapeutic cancer vaccines, potentially transforming treatment strategies by enabling rapid, patient-specific vaccine development. The framework's integration of multiple data modalities and AI-driven design principles offers promising implications for improving cancer immunotherapy outcomes and advancing precision medicine approaches in oncology.

The FDA approval of daraxonrasib (Rasonque), an oral pan-RAS inhibitor, marks a significant advancement in pancreatic cancer treatment. This approval represents a major breakthrough after decades of unsuccessful attempts to target RAS mutations, which occur in approximately 90-92% of pancreatic adenocarcinomas. The approval was supported by the phase 3 RASolute 302 trial, which randomized 500 patients with metastatic pancreatic adenocarcinoma whose disease had progressed after one prior systemic therapy line to receive either daraxonrasib or standard chemotherapy. Daraxonrasib demonstrated compelling efficacy, nearly doubling median overall survival to 13.2 months compared to 6.7 months with chemotherapy (HR 0.40; P<0.0001). Progression-free survival improved to 7.2 months versus 3.6 months (HR 0.49; P<0.0001), with objective response rates of 30% versus 11%. As a pan-RAS inhibitor blocking all RAS signaling, daraxonrasib provides a transformative treatment option for both therapy-resistant patients and those ineligible for multi-agent chemotherapy, fundamentally changing pancreatic cancer management approaches.

Laboratory results have traditionally marked the endpoint of clinical diagnosis, but precision medicine has transformed them into trial enrollment gateways. Today, biomarker testing determines patient eligibility and trial arm assignment, yet access remains fragmented and results often arrive in formats that matching systems cannot process. The fundamental challenge is diagnostic rather than enrollment-related. Pathology reports delivered via fax or unstructured PDFs require optical character recognition, which introduces errors that exclude eligible patients. The solution lies in reporting results as structured, coded data capturing analytes, values, methods, and specimen details—information that flows directly into patient-matching algorithms rather than remaining trapped in clinical documents. Large language models show promise in synthesizing structured and unstructured patient records across diagnosis, treatment history, and prior response, though clinician judgment remains essential for confirming genuine matches. A critical but often overlooked issue is timeline misalignment: while trials schedule eligibility testing at screening, labs require separate development timelines to validate assays. Bridging these gaps through standardized data architecture and integrated lab-sponsor planning is essential to making diagnostic testing truly functional for precision medicine trials.

Diabetes mellitus remains a significant global health challenge due to rising incidence rates and limitations of conventional treatment approaches, particularly regarding poor drug bioavailability, frequent dosing requirements, and lack of real-time glucose regulation. Recent advances in nanotechnology offer promising solutions for diabetes prevention, diagnosis, and management through smart health and precision medicine applications. This review examines emerging nanostructure-based innovations across two critical domains: glucose monitoring and therapeutic delivery. Novel drug delivery systems leverage nanoparticles, liposomes, sustained-release implants, and microneedles to enhance insulin bioavailability, reduce enzymatic degradation, and improve patient adherence while minimizing side effects. Glucose-responsive smart devices represent a breakthrough, delivering medication only during hyperglycemic episodes. Simultaneously, nanotechnology-enabled biosensors and wearable devices have revolutionized glucose monitoring with enhanced sensitivity and specificity, integrating seamlessly with digital healthcare platforms. The synergy between nanotechnology, artificial intelligence, and real-world health data enables personalized diabetes management through predictive monitoring and adaptive insulin delivery systems. However, clinical translation barriers, biosafety concerns, and regulatory challenges remain obstacles. Continued interdisciplinary collaboration among materials scientists, bioengineers, and clinicians is essential to fully realize nanotechnology's potential in transforming diabetes care and substantially improving patient outcomes.

CAR-T cell therapy has transformed the treatment of several haematological malignancies, but its impact in solid tumours has remained frustratingly limited. Now, a new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers associated with conventional cell therapy.

Cell and gene therapies are transforming the pharmaceutical industry, but commercial success requires coordinated planning across manufacturing, regulation, market access, reimbursement, supply chains, patient identification, and long-term value demonstration.

Breast cancer treatment is shifting from conventional chemotherapy toward targeted therapies, antibody-drug conjugates and biomarker-driven combinations, creating new opportunities for precision oncology and pharmaceutical innovation.

In the ESR1-mutated subgroup of EMBER-3, adding imlunestrant plus abemaciclib doubled median progression-free survival from 5.5 to 11.1 months, with a hazard ratio of 0.53. The approval therefore establishes another biomarker-defined treatment option for ER-positive/HER2-negative metastatic breast cancer after endocrine progression and further strengthens the clinical importance of identifying ESR1 mutations during the course of disease.

The International Myeloma Foundation's medical editorial team has compiled a comprehensive clinical update covering multiple myeloma research published in August-September 2026, reviewed by Dr. Joseph Mikhael. The update addresses diagnosis, risk stratification, and management of both multiple myeloma and smoldering multiple myeloma (SMM). Multiple myeloma diagnosis requires ≥10% clonal bone marrow plasma cells or biopsy-proven plasmacytoma with at least one myeloma-defining event, including CRAB features or biomarkers such as ≥60% clonal plasma cells, serum free light chain ratio ≥100, or >1 focal lesion on MRI. Current treatment incorporates anti-CD38 monoclonal antibodies (daratumumab or isatuximab), bortezomib, lenalidomide, and dexamethasone, potentially followed by autologous stem cell transplantation. Relapsed disease management includes CAR-T cell therapy, bispecific antibodies, and belantamab mafodotin. Notably, the AQUILA randomized trial demonstrated that three years of daratumumab in high-risk SMM patients significantly delayed progression to active myeloma and improved survival, achieving 63.1% versus 40.8% five-year progression-free survival compared with active monitoring alone.

This open-access review examines nucleic acid-based antimicrobial strategies as emerging therapeutic approaches against drug-resistant Staphylococcus aureus, a major public health threat. The article comprehensively analyzes the mechanisms of action underlying nucleic acid therapeutics, including antisense oligonucleotides, small interfering RNAs, and aptamers, which target bacterial pathogenicity factors and resistance mechanisms. The review critically evaluates various delivery approaches essential for effective antimicrobial efficacy, such as nanoparticle carriers, liposomes, and conjugation strategies that enhance bacterial cell penetration and bioavailability. Published in Infectious Diseases and Therapy in September 2026, this work addresses the growing clinical challenge of methicillin-resistant S. aureus and other resistant strains by exploring how nucleic acid therapeutics can modulate virulence genes and resistance pathways. The significance lies in identifying alternative treatment paradigms beyond conventional antibiotics, offering potential solutions to antimicrobial resistance while reducing selective pressure. This comprehensive analysis provides valuable insights for researchers and clinicians developing next-generation therapeutic options for difficult-to-treat staphylococcal infections.

Genentech announced positive results from its Phase III evERA trial evaluating giredestrant, an oral estrogen receptor degrader, in combination therapy for estrogen receptor-positive advanced breast cancer. The study demonstrated that giredestrant significantly improved progression-free survival compared to standard treatment, marking an important advancement in hormone-positive breast cancer management. These findings were published in The New England Journal of Medicine, underscoring their clinical significance. Giredestrant represents a novel therapeutic approach by degrading estrogen receptors rather than simply blocking them, offering potential benefits for patients with advanced ER-positive disease who may have limited options. The evERA trial data support giredestrant's role as a meaningful treatment option, potentially expanding the therapeutic landscape for this common breast cancer subtype. This development is particularly relevant for oncology stakeholders, as it demonstrates continued innovation in precision medicine for hormone-dependent cancers and may influence treatment guidelines and clinical practice patterns for ER-positive advanced breast cancer management.

Personalized neoantigen vaccines represent an emerging precision oncology approach that harnesses patient-specific immunotherapy by targeting tumor-restricted antigens derived from genomic and transcriptomic alterations, including single-nucleotide variants, insertions, deletions, frameshifts, gene fusions, and aberrant splicing events. Early clinical studies have demonstrated manufacturing feasibility and immunogenicity, while randomized phase 2b evidence in resected melanoma patients has shown promising clinical activity signals requiring confirmation in larger trials. However, clinical development remains concentrated in high-income academic centers, prompting concerns about equitable implementation across Southeast Asia. This review examines published clinical evidence and health-system capacity across the eleven ASEAN member states, revealing heterogeneous regional capabilities. While several countries possess national genomic programs and tertiary molecular services, routine nationwide availability, public reimbursement, and equitable geographic access remain inadequately characterized. Critical implementation barriers include access to clinical-grade tumor-normal sequencing, bioinformatics expertise, patient-specific GMP manufacturing, and temperature-controlled distribution. Current immunopeptidomic training datasets demonstrate uneven HLA coverage across Southeast Asian populations. The authors propose a staged hub-and-spoke model linking clinical centers with regional GMP facilities to support prospective implementation studies, emphasizing that whether these vaccines reduce or widen existing cancer inequities depends on evidence-based patient selection, health-system investment, and sustainable financing.

Following successful negotiations, the Cell and Gene Therapy Access Model has established outcomes-based agreements (OBAs) between the Centers for Medicare & Medicaid Services and two gene therapy manufacturers—Genetix Biotherapeutics Inc. and Vertex Pharmaceuticals Incorporated—for treating severe sickle cell disease. Currently, 32 states plus the District of Columbia and Puerto Rico, collectively representing 84% of Medicaid beneficiaries with sickle cell disease, participate in the model. Seven participating states and the District of Columbia received Cooperative Agreement awards beginning August 1, 2025. Under OBAs, payment to manufacturers is tied to patients' health outcomes over defined periods; if therapies underperform expectations, manufacturers reimburse payers proportionally. This approach eliminates the need for individual state-level negotiations by enabling CMS to negotiate multi-state agreements while managing financial reconciliation, clinical outcome measures, and performance evaluation. The model's significance lies in improving access to expensive gene therapies while managing financial risk through performance accountability, ultimately benefiting Medicaid beneficiaries seeking life-changing treatments.

This systematic review and network meta-analysis evaluated the efficacy and cost-effectiveness of first-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma in the Chinese healthcare context. Researchers analyzed seven Phase III randomized controlled trials encompassing 4,973 patients, comparing ICI-targeted combinations against sunitinib using network meta-analysis to assess progression-free survival and overall survival outcomes. A partitioned survival model was subsequently developed to conduct cost-effectiveness analysis over a 20-year horizon. Results demonstrated that pembrolizumab plus lenvatinib ranked highest for progression-free survival, while toripalimab plus axitinib achieved superior overall survival outcomes and the lowest incremental cost-effectiveness ratio at $62,204.37 per quality-adjusted life-year. However, all evaluated regimens exceeded the willingness-to-pay threshold of $40,332.35 per quality-adjusted life-year established for the Chinese healthcare system. These findings provide critical insights for healthcare policy makers and clinicians regarding the clinical benefits and economic implications of combining immune checkpoint inhibitors with targeted therapies in treating advanced renal cell carcinoma.

Pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's most lethal cancers, with only 13.7% five-year survival rates and even grimmer outcomes in previously treated metastatic settings, where median overall survival is five to seven months. Despite KRAS mutations driving over 90% of pancreatic cancers for decades, the protein remained undruggable until recently due to its lack of well-defined pockets amenable to small-molecule inhibitors. While sotorasib and adagrasib, approved in 2021 and 2022 respectively, represented landmark breakthroughs by targeting the G12C mutation, this variant accounts for only 1-2% of PDAC cases. More prevalent mutations include G12D (40%), G12V (30%), and G12R (20%), necessitating alternative approaches. Daraxonrasib, a pan-RAS inhibitor, addresses this gap by targeting mutant and wild-type KRAS, HRAS, and NRAS isoforms in their active state. The drug forms a complex with cyclophilin A upon cellular entry, enabling high affinity binding to active RAS and overcoming previously insurmountable barriers. This innovation could transform treatment for the majority of PDAC patients currently lacking targeted options.

Allogeneic CAR-T cell therapy represents a significant advancement in treating T-cell malignancies, offering substantial scalability advantages over autologous approaches. Unlike autologous CAR-T therapies that require patient-specific cell engineering, allogeneic CAR-T utilizes donor-derived cells that can be manufactured at scale from a single source, dramatically reducing production time and costs while increasing accessibility. The primary challenge involves managing graft-versus-host disease (GVHD), a potentially severe complication arising when donor immune cells attack recipient tissues. Recent developments have focused on engineering strategies to mitigate GVHD risk while preserving the therapeutic anti-tumor effects. By implementing off-the-shelf manufacturing protocols and refined cell engineering techniques, developers can produce consistent, high-quality allogeneic CAR-T products suitable for broader patient populations. This scalability potential positions allogeneic CAR-T as a transformative approach in oncology, particularly for treating T-cell malignancies where rapid, standardized treatment deployment is critical. The technology's commercial viability depends on successfully balancing safety profiles with manufacturing efficiency.

The Cell and Gene Therapy (CGT) Access Model represents a groundbreaking federal initiative designed to expand access to innovative treatments for rare and severe diseases through outcomes-based agreements (OBAs) negotiated by the Centers for Medicare & Medicaid Services on behalf of state Medicaid agencies. This multi-year, voluntary model marks the first time the federal government has engaged in such negotiations with CGT manufacturers. The initial focus targets gene therapy treatments for sickle cell disease, a genetic blood disorder affecting Medicaid beneficiaries. States and manufacturers entered the program through a Request for Application process, with participation beginning between January 2025 and January 2026. The model aims to increase patient access to potentially transformative treatments while improving health outcomes and reducing costs to state Medicaid programs. Recognizing that gene therapy for sickle cell disease requires extended inpatient hospital stays and myeloablative chemotherapy that causes infertility, the model mandates participating manufacturers cover fertility preservation services. This comprehensive approach addresses both treatment access and critical patient support needs, with potential expansion to additional disease conditions in the future.

Chimeric antigen receptor (CAR) T-cell therapy has traditionally been accessible only through tertiary academic centers, creating significant barriers for patients in community settings. At the Community Oncology Alliance Payer Exchange & Innovation Summit, payer, provider, and network leaders convened to address this gap and establish pathways for expanding CAR T access to community oncology practices. The panel, moderated by Kiana Mehring from Florida Cancer Specialists & Research Institute, featured Anthony Bonagura from Optum, Aaron Lyss from OneOncology, and Ameet Patel from FCSRI. Participants identified three key success metrics: clinical outcomes matching those at academic centers, faster and improved patient access, and manageable financial burden for community practices. A critical innovation discussed was "brain-to-vein" time—the period from initial diagnosis to cellular therapy administration—where delays cause approximately 20 to 25 percent of patients to become ineligible. Panelists emphasized that success requires balancing diverse stakeholder expectations, including patient preferences, employer cost concerns, and the unrecognized work of care navigators and coordinators. This collaborative effort signals industry recognition that decentralizing CAR T access is essential for equitable patient care delivery.